文献速递肝胆胰外科胃肠外科

解析结直肠癌肝转移中的BRAF突变状态:多中心协作回答6个开放临床问题

Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions.
PubMed 文献 · Ann Surg · 2022-12-01

该多中心回顾性研究纳入240例接受肝切除的BRAF突变结直肠癌肝转移患者,比较V600E与非V600E突变、KRAS共突变、微卫星状态、初始可切除与转化后切除、肝外转移与否及肝内复发再切除与保守治疗的生存差异。V600E突变总生存较差,MSS无复发生存较差,肝外转移总生存极差,复发后再肝切除可改善总生存。

要点

  • BRAF V600E突变者总生存显著短于非V600E突变者。
  • 肝外转移者总生存极差,手术可能无效。
  • 肝内复发后再次肝切除可改善总生存。

核心结论

  • BRAF突变结直肠癌肝转移伴肝外转移者手术可能无效。
  • 无肝外转移的转化后切除可获得令人鼓舞的生存。
  • 选择患者行二次肝切除与改善结局相关。

研究设计与样本

  • 多中心协作回顾性研究,从前瞻性维护的登记库中识别接受肝切除的BRAF突变结直肠癌肝转移患者240例。

主要发现

  • V600E突变总生存30.6个月 vs 非V600E 144个月,P=0.004,无复发生存无差异。
  • MSS无复发生存9.1个月 vs MSI-high 26个月,P<0.001,总生存无差异(33.5 vs 41个月,P=0.3)。
  • 转化后切除无复发生存8个月 vs 初始可切除11个月,P=0.01,总生存相似(30 vs 40个月,P=0.4)。
  • 肝外转移总生存8.8个月 vs 肝局限40个月,P<0.001。
  • 肝内复发再肝切除总生存41个月 vs 非手术18.7个月,P=0.004。

关键数值与推荐

  • BRAF V600E突变总生存30.6 vs 144个月(P=0.004)。
  • MSS无复发生存9.1 vs 26个月(P<0.001)。
  • 肝外转移总生存8.8 vs 40个月(P<0.001)。
  • 再肝切除总生存41 vs 18.7个月(P=0.004)。

临床怎么用

  • BRAF突变结直肠癌肝转移伴肝外转移者应慎重选择手术。
  • 无肝外转移的转化后切除可考虑积极手术。
  • 肝内复发选择患者行二次肝切除可能改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the clinical implications of BRAF -mutated (mut BRAF ) colorectal liver metastases (CRLMs). BACKGROUND: The clinical implications of mut BRAF status in CRLMs are largely unknown. METHODS: Patients undergoing resection for mut BRAF CRLM were identified from prospectively maintained registries of the collaborating institutions. Overall survival (OS) and recurrence-free survival (RFS) were compared among patients with V600E versus non-V600E mutations, KRAS/BRAF comutation versus mut BRAF alone, microsatellite stability status (Microsatellite Stable (MSS) vs instable (MSI-high)), upfront resectable versus converted tumors, extrahepatic versus liver-limited disease, and intrahepatic recurrence treated with repeat hepatectomy versus nonoperative management. RESULTS: A total of 240 patients harboring BRAF -mutated tumors were included. BRAF V600E mutation was associated with shorter OS (30.6 vs 144 mo, P =0.004), but not RFS compared with non-V600E mutations. KRAS/BRAF comutation did not affect outcomes. MSS tumors were associated with shorter RFS (9.1 vs 26 mo, P <0.001) but not OS (33.5 vs 41 mo, P =0.3) compared with MSI-high tumors, whereas patients with resected converted disease had slightly worse RFS (8 vs 11 mo, P =0.01) and similar OS (30 vs 40 mo, P =0.4) compared with those with upfront resectable disease. Patients with extrahepatic disease had worse OS compared with those with liver-limited disease (8.8 vs 40 mo, P <0.001). Repeat hepatectomy after intrahepatic recurrence was associated with improved OS compared with nonoperative management (41 vs 18.7 mo, P =0.004). All results continued to hold true in the multivariable OS analysis. CONCLUSIONS: Although surgery may be futile in patients with BRAF -mutated CRLM and concurrent extrahepatic disease, resection of converted disease resulted in encouraging survival in the absence of extrahepatic spread. Importantly, second hepatectomy in select patients with recurrence was associated with improved outcomes. Finally, MSI-high status identifies a better prognostic group, with regard to RFS while patients with non-V600E mutations have excellent prognosis.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Margonis GA, Boerner T, Bachet JB, et al. Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions. Ann Surg. 2022. PMID: 36453261. doi:10.1097/SLA.0000000000005771

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。